PMID- 9030962
OWN - NLM
STAT- MEDLINE
DCOM- 19970326
LR  - 20191101
IS  - 1269-3286 (Print)
IS  - 1269-3286 (Linking)
VI  - 38
IP  - 6
DP  - 1996 Dec
TI  - Flow cytometry study of cell cycle, apoptosis and drug resistance in acute 
      leukemia.
PG  - 495-504
AB  - The response to therapy of leukemic cells is largely determined by their capacity 
      of proliferation and apoptosis in presence of the administered drugs. We describe 
      here the main markers used in flow cytometry (FCM) and involved in the assessment 
      of cell cycle parameters: single labeling by Propidium Iodide (PI) and double 
      labeling anti-Bromodeoxyuridine (BrdUrd)/PI which, both in vitro and in vivo, 
      gives cell percentages in the different cell cycle phases. The markers of cell 
      cycle progression can be divided into proliferation markers such as PCNA 
      (proliferating cell nuclear antigen) or Ki-67 and cell cycle progression markers. 
      The latter, which are the core of the cell cycle machinery, are molecules 
      recently characterized (Cyclins, CDKs (cell dependent kinases), CDIs 
      (cyclin-dependent kinase inhibitors)) and their cell expression can be analyzed 
      using FCM. FCM is also one of the best means to detect and quantitate apoptotic 
      cells. Several techniques are described: Nuclear labeling using Hoechst 33342: 
      mitochondrial labeling using DiOC6(3): detection of DNA fragmentation using 1) 
      labeling of fixed and permeabilized cells with a DNA marker or 2) labeling of the 
      free 3' DNA ends using incorporation of labeled deoxynucleotides; detection in 
      apoptotic cells (Bcl-2, Fas, phospholipids...). At last, we analyzed flow 
      cytometry methods to study the cell resistance to Ara-C and anthracyclins. In 
      combination with cell kinetic studies and detection of apoptotic cells, they 
      should increase the efficiency of the acute leukemia treatment.
FAU - Lacombe, F
AU  - Lacombe F
AD  - Laboratoire d'Hematologie, CHR Bordeaux, Hopital Haut-Leveque, France.
FAU - Belloc, F
AU  - Belloc F
LA  - eng
PT  - Journal Article
PT  - Review
PL  - France
TA  - Hematol Cell Ther
JT  - Hematology and cell therapy
JID - 9613253
RN  - 0 (Biomarkers)
RN  - 0 (Proliferating Cell Nuclear Antigen)
SB  - IM
MH  - Acute Disease
MH  - Apoptosis/*physiology
MH  - Biomarkers/analysis
MH  - Cell Cycle/*physiology
MH  - Drug Resistance/*physiology
MH  - Flow Cytometry
MH  - Humans
MH  - Leukemia/*pathology/*physiopathology
MH  - Proliferating Cell Nuclear Antigen/analysis
RF  - 52
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1007/s00282-996-0495-9 [doi]
PST - ppublish
SO  - Hematol Cell Ther. 1996 Dec;38(6):495-504. doi: 10.1007/s00282-996-0495-9.